The cell and gene therapy (CGT) industry achieved a significant milestone at the end of 2022: the first approval of an allogeneic T-cell therapy in the world.
The proposed EHDS Regulation1 (Proposal), introduced in May 2022 by the European Commission (EC), aims to reform the “situation of fragmentation” that depicts th
